Can Dietary Restriction Drugs Unlock Longevity Without Starvation?

Dietary restriction (DR) has been used for thousands of years, often for cultural or health reasons. But only in the last 30 years have scientists begun unravelling how it affects the body at a cellular level. Today, research shows that carefully controlled DR can trigger biological changes that may slow ageing and protect against diseases like Alzheimer's and Parkinson's.

Recent studies now focus on replicating these benefits without strict food reduction. Drugs that mimic DR's effects—particularly those targeting metabolic pathways—are being tested in clinical trials worldwide.

DR works by activating key biological processes that improve cell function. Autophagy, a process that clears damaged cells, is boosted by DR and helps combat neurodegenerative diseases. At the same time, pathways like AMPK and mTORC1—both sensitive to nutrient levels—play opposing roles in stress resistance and longevity. AMPK promotes energy conservation and repair, while mTORC1, when suppressed, reduces cell growth and extends lifespan.

Another critical factor is NAD+ metabolism, which supports mitochondria, stabilises DNA, and controls inflammation. Sirtuins, a family of proteins activated by DR, further enhance these protective effects. Yet DR isn't without risks: excessive restriction can weaken the immune system and slow wound healing, meaning balance is essential.

In the last five years, researchers have explored whether drugs can replicate DR's benefits. At least 12 clinical trials have tested GLP-1 receptor agonists—such as semaglutide and liraglutide—as potential DR mimetics. Five of these are Phase II or III trials for Parkinson's disease, including studies like Exenatide-PD3 at Imperial College London (2022–2025) and the NIH's Lixisenatide-PD trial (2023–ongoing). Seven more trials focus on Alzheimer's, such as Novo Nordisk's Semaglutide-ALZ (2024–2026) and the University of Edinburgh's Liraglutide-ELAD (2021–2024). These studies measure improvements in motor function and cognition using randomised, double-blind methods across Europe, the USA, and Asia.

The shift from viewing DR as a cultural practice to a scientific tool has opened new possibilities. By targeting pathways like autophagy, FGF21, and GLP-1R activity, researchers hope to develop therapies that offer DR's advantages without its challenges.

The link between DR and longevity is now supported by decades of molecular research. Clinical trials are testing whether drugs can safely reproduce these effects in humans. If successful, such treatments could provide a way to delay age-related diseases—without requiring extreme dietary changes.

For now, the findings highlight the need for precise approaches, as both too much and too little restriction carry risks. The next few years will reveal whether these scientific advances can translate into real-world benefits for patients.